MAPT and Alzheimer disease: We suggest that for immunomodulation to be more successful, the methodology must show efficacy against all the key pathologies in AD: amyloid plaques, CAA, tau related pathology, and toxic oligomer species, with a few or no associated microhemorrhages [2,10].